Boston, MA -- (SBWIRE) -- 02/05/2014 -- Global Market Direct's pharmaceuticals report, "ReNeuron Group plc - Product Pipeline Review - 2013" provides data on the ReNeuron Group plc's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct's proprietary databases, ReNeuron Group plc's corporate website, SEC filings, investor presentations and featured press releases, both from ReNeuron Group plc and industry-specific third party sources, put together by Global Markets Direct's team.
View Full Report Details and Table of Contents
- ReNeuron Group plc - Brief ReNeuron Group plc overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of ReNeuron Group plc human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of ReNeuron Group plc with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the ReNeuron Group plc's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to Get This Report
- Evaluate ReNeuron Group plc's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of ReNeuron Group plc in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the ReNeuron Group plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with ReNeuron Group plc.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of ReNeuron Group plc and identify potential opportunities in those areas.
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- ReNeuron Group plc - Product Pipeline Review - 2012
- Vectura Group plc - Product Pipeline Review - 2013
- ReNeuron Group plc (RENE) - Financial and Strategic SWOT Analysis Review
- AstraZeneca PLC - Product Pipeline Review - 2013
- Evocutis PLC - Product Pipeline Review - 2013
- GlaxoSmithKline plc - Product Pipeline Review - 2013
- Peripheral Artery Occlusive Disease (PAOD) - Pipeline Review, H1 2013
- Simcere Pharmaceutical Group - Product Pipeline Review - 2013
- Alkermes Plc - Product Pipeline Review - 2013
- Shire Plc - Product Pipeline Review - 2013